Cannabis dispensary staff approaches to counseling on potential contraindications to cannabis use: insights from a national self-report survey.
Cannabis
Health policy
Medical cannabis
Medication safety
Journal
BMC primary care
ISSN: 2731-4553
Titre abrégé: BMC Prim Care
Pays: England
ID NLM: 9918300889006676
Informations de publication
Date de publication:
14 07 2023
14 07 2023
Historique:
received:
22
04
2022
accepted:
28
06
2023
medline:
17
7
2023
pubmed:
14
7
2023
entrez:
13
7
2023
Statut:
epublish
Résumé
Legal cannabis is available in more than half of the United States. Health care professionals (HCPs) rarely give recommendations on dosing or safety of cannabis due to limits imposed by policy and lack of knowledge. Customer-facing cannabis dispensary staff, including clinicians (pharmacists, nurses, physician's assistants), communicate these recommendations in the absence of HCP recommendations. Little is known about how dispensary staff approach individuals with complex medical and psychiatric comorbidities. Using responses from a national survey, we describe how cannabis dispensary staff counsel customers with medical and psychiatric comorbidities on cannabis use and examine whether state-specific cannabis policy is associated with advice given to customers. National, cross-sectional online survey study from February 13, 2020 to October 2, 2020 of dispensary staff at dispensaries that sell delta-9-tetrahydrocannabinol containing products. Measures include responses to survey questions about how they approach customers with medical and psychiatric comorbidities; state medicalization score (scale 0-100; higher score indicates more similarity to regulation of traditional pharmacies); legalized adult-use cannabis (yes/no). We conducted multiple mixed effects multivariable logistic regression analyses to understand relationships between state medicalization and dispensary employees' perspectives. Of 434 eligible respondents, most were budtenders (40%) or managers (32%), and a minority were clinicians (18%). State medicalization score was not associated with responses to most survey questions. It was associated with increased odds of encouraging customers with medical comorbidities to inform their traditional HCP of cannabis use (Odds ratio [OR]=1.2, 95% confidence interval [CI] 1.0-1.4, p=0.03) and reduced odds of recommending cannabis for individuals with cannabis use disorder (CUD) (OR=0.8, 95% CI 0.7-1.0, p=0.04). Working in a state with legalized adult-use cannabis was associated with recommending traditional health care instead of cannabis in those with serious mental illness (OR 2.2, 95% CI 1.1-4.7, p=0.04). Less than half of respondents believed they had encountered CUD (49%), and over a quarter did not believe cannabis is addictive (26%). When managing cannabis dosing and safety in customers with medical and psychiatric comorbidity, dispensary staff preferred involving individuals' traditional HCPs. Dispensary staff were skeptical of cannabis being addictive. While state regulations of dispensaries may impact the products individuals have access to, they were not associated with recommendations that dispensary staff gave to customers. Alternative explanations for dispensary recommendations may include regional or store-level variation not captured in this analysis.
Sections du résumé
BACKGROUND
Legal cannabis is available in more than half of the United States. Health care professionals (HCPs) rarely give recommendations on dosing or safety of cannabis due to limits imposed by policy and lack of knowledge. Customer-facing cannabis dispensary staff, including clinicians (pharmacists, nurses, physician's assistants), communicate these recommendations in the absence of HCP recommendations. Little is known about how dispensary staff approach individuals with complex medical and psychiatric comorbidities. Using responses from a national survey, we describe how cannabis dispensary staff counsel customers with medical and psychiatric comorbidities on cannabis use and examine whether state-specific cannabis policy is associated with advice given to customers.
METHODS
National, cross-sectional online survey study from February 13, 2020 to October 2, 2020 of dispensary staff at dispensaries that sell delta-9-tetrahydrocannabinol containing products. Measures include responses to survey questions about how they approach customers with medical and psychiatric comorbidities; state medicalization score (scale 0-100; higher score indicates more similarity to regulation of traditional pharmacies); legalized adult-use cannabis (yes/no). We conducted multiple mixed effects multivariable logistic regression analyses to understand relationships between state medicalization and dispensary employees' perspectives.
RESULTS
Of 434 eligible respondents, most were budtenders (40%) or managers (32%), and a minority were clinicians (18%). State medicalization score was not associated with responses to most survey questions. It was associated with increased odds of encouraging customers with medical comorbidities to inform their traditional HCP of cannabis use (Odds ratio [OR]=1.2, 95% confidence interval [CI] 1.0-1.4, p=0.03) and reduced odds of recommending cannabis for individuals with cannabis use disorder (CUD) (OR=0.8, 95% CI 0.7-1.0, p=0.04). Working in a state with legalized adult-use cannabis was associated with recommending traditional health care instead of cannabis in those with serious mental illness (OR 2.2, 95% CI 1.1-4.7, p=0.04). Less than half of respondents believed they had encountered CUD (49%), and over a quarter did not believe cannabis is addictive (26%).
CONCLUSIONS
When managing cannabis dosing and safety in customers with medical and psychiatric comorbidity, dispensary staff preferred involving individuals' traditional HCPs. Dispensary staff were skeptical of cannabis being addictive. While state regulations of dispensaries may impact the products individuals have access to, they were not associated with recommendations that dispensary staff gave to customers. Alternative explanations for dispensary recommendations may include regional or store-level variation not captured in this analysis.
Identifiants
pubmed: 37442944
doi: 10.1186/s12875-023-02095-5
pii: 10.1186/s12875-023-02095-5
pmc: PMC10347704
doi:
Substances chimiques
Medical Marijuana
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
145Informations de copyright
© 2023. The Author(s).
Références
Ann Intern Med. 2020 Aug 4;173(3):248-249
pubmed: 32745455
Eur J Intern Med. 2018 Mar;49:12-19
pubmed: 29307505
J Am Board Fam Med. 2013 Jan-Feb;26(1):52-60
pubmed: 23288281
J Pain. 2019 Nov;20(11):1362-1372
pubmed: 31132510
J Stud Alcohol Drugs. 2012 Sep;73(5):820-8
pubmed: 22846246
J Psychoactive Drugs. 2019 Nov-Dec;51(5):400-404
pubmed: 31264536
Cannabis Cannabinoid Res. 2016 Dec 01;1(1):244-251
pubmed: 28861496
Cannabis Cannabinoid Res. 2021 Feb 12;6(1):58-65
pubmed: 33614953
Addiction. 2008 Mar;103(3):439-49; discussion 450-1
pubmed: 18269364
JAMA. 2015 Jun 23-30;313(24):2456-73
pubmed: 26103030
J Law Med. 2019 Jul;26(4):815-824
pubmed: 31682359
PLoS One. 2013 Oct 24;8(10):e76635
pubmed: 24204649
Medicines (Basel). 2018 Dec 23;6(1):
pubmed: 30583596
Am J Psychiatry. 2013 Aug;170(8):834-51
pubmed: 23903334
Am J Public Health. 2017 Aug;107(8):e1-e12
pubmed: 28644037
Cannabis Cannabinoid Res. 2018 Mar 01;3(1):74-84
pubmed: 29662957
J Prim Care Community Health. 2019 Jan-Dec;10:2150132719884838
pubmed: 31646929
JAMA Netw Open. 2021 Sep 1;4(9):e2124511
pubmed: 34524435
PRiMER. 2017 Oct 13;1:20
pubmed: 32944706
J Cannabis Res. 2021 Jul 2;3(1):22
pubmed: 34215346
JAMA Psychiatry. 2016 Mar;73(3):292-7
pubmed: 26842658
J Pain. 2019 Jul;20(7):830-841
pubmed: 30690169
Psychol Addict Behav. 2016 May;30(3):389-97
pubmed: 26828641
JAMA Netw Open. 2021 May 3;4(5):e219375
pubmed: 33956129
J Health Econ. 2014 Dec;38:43-61
pubmed: 25205609
Int J Drug Policy. 2017 Apr;42:30-35
pubmed: 28189912
Health Aff (Millwood). 2019 Feb;38(2):295-302
pubmed: 30715980
Med Clin North Am. 2022 Jan;106(1):131-152
pubmed: 34823727
Int J Drug Policy. 2021 Aug;94:103202
pubmed: 33765514
Epidemiology. 1990 Jan;1(1):43-6
pubmed: 2081237
Can Fam Physician. 2014 Sep;60(9):801-8, e423-32
pubmed: 25217674
Am J Hosp Palliat Care. 2017 Feb;34(1):85-91
pubmed: 26377551